Post neoadjuvant management in BRCA mutant breast cancer patients
Post neoadjuvant management in BRCA mutant breast cancer patients
The 2022 OncoAlert Colloquium Day 6: EONS Sessions
The 2022 OncoAlert Colloquium Day 5: GI Oncology
The 2022 OncoAlert Colloquium Day 4: ESGO Sessions and Gynaecological Oncology
The 2022 OncoAlert Colloquium Day 3: Lung Cancer
The 2022 OncoAlert Colloquium Day 2: GU Oncology
The 2022 OncoAlert Colloquium Day 1: Breast Cancer
NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer
Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and OS in CLDN18.2+/ HER2 mG/GEJ adenocarcinoma
Elacestrant shows improved PFS in ER-positive/HER2-negative mBC
ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL
ASH 2022: Multiple myeloma roundup